REGN - Intellia opts out of hemophilia pact with Regeneron
2024-03-22 12:40:30 ET
Intellia Therapeutics ( NASDAQ: NTLA ) is opting out of an agreement with Regeneron Pharmaceuticals ( NASDAQ: REGN ) to co-develop a factor IX gene editing therapy for hemophilia A and B, the biotechnology firm disclosed in a filing on Friday....
Intellia opts out of hemophilia pact with Regeneron